TP53 and acute myeloid leukemia: Dysfunction of p53 leads to an accumulation of mutations, increasing the risk of cancer (Wiederschain et al., 2005; Meyer et al., 2009), and alterations such as microsatellite instability or p53 mutations were enriched substantially in patients with therapy-related AML (Wiederschain et al., 2005; Meyer et al., 2009).